Last reviewed · How we verify
NCT05328765: ACTION HIV
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
trial in Anal Squamous Cell Carcinoma in 300 participants. Currently enrolling.
24 April 2025
Quick facts
| Lead sponsor | Latin American Cooperative Oncology Group |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 9 June 2023 |
| Primary completion | 24 April 2025 |
| Estimated completion | 24 April 2025 |
| Sites | 1 location across Brazil |
Conditions studied
- Anal Squamous Cell Carcinoma — all drugs for Anal Squamous Cell Carcinoma →
- HIV Infections — all drugs for HIV Infections →
Sponsor
Latin American Cooperative Oncology Group
Who can join
18 and older, any sex, with Anal Squamous Cell Carcinoma or HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity \[IMRT\], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05328765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
- NCT06050707 — MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach · Phase 2 · recruiting
- NCT05838391 — Adaptive Radiation in Anal Cancer · NA · recruiting
- NCT04929028 — Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer · Phase 2 · active not recruiting
- NCT05438836 — Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer · recruiting
Other Latin American Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
- NCT06822543 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastas · Phase 2 · recruiting
- NCT06527690 — Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficien · Phase 2 · withdrawn
- NCT06279442 — Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort · recruiting
- NCT06014580 — Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05328765 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Latin American Cooperative Oncology Group
- Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05328765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing